Notably, LB-100-induced anti-tumor activity in vivo was largely compromised against tumors that were derived from AMPKα1-knockout (by CRISPR/Cas9 method) HCT-116 cells (“+AMPKα1 KO”, Figure 6A-6C). The gene discussed is PRKAA1; the disease is neoplasm.